<DOC>
	<DOCNO>NCT00378287</DOCNO>
	<brief_summary>The purpose study demonstrate patient oral rabeprazole produce equivalent acid suppression intravenous pantoprazole Day 1 drug administration .</brief_summary>
	<brief_title>A Study Monitor Intragastric pH Patients Taking Rabeprazole v . Patients Taking Pantoprazole</brief_title>
	<detailed_description>Following screen determine eligibility ( normal medical history , physical examination include vital sign , laboratory finding , negative test active H. pylorus infection , negative pregnancy test applicable ) subsequent enrolment , patient baseline 24-hour intragastric pH record . Patients receive either oral rabeprazole 20mg intravenous pantoprazole 40mg daily 3 consecutive day . For blind purpose , patient also receive either placebo oral tablet placebo intravenous solution ( `` double-dummy '' design ) . A 24-hour intragastric pH record complete Day 1 Day 3 drug administration period . This follow 14-day washout period second 3-day drug administration period patient receive crossover drug regimen , 24-hour intragastric pH recording complete first third day second drug administration period.Thirty-seven patient negative test active H. pylorus infection test randomise study . The primary hypothesis oral rabeprazole produce equivalent acid suppression intravenous pantoprazole indicate time intragastric pH great 4 Day 1 drug administration . Eligible patient randomly assign 1 2 treatment group first receive either oral rabeprazole 20mg plus placebo intravenous solution intravenous pantoprazole 40mg plus placebo oral tablet daily 3 consecutive day . After 14-day washout , patient receive crossover drug regimen . Rabeprazole : supply 20mg tablet ( match placebo tablet ) . Pantoprazole : supply 12-mL vial lyophilize powder contain pantoprazole 40mg ( pantoprazole</detailed_description>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Female patient must postmenopausal ( least 1 year ) , sterile ( 6 month poststerilization ) , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) entry throughout study . Patients childbearing potential ( include use birth control ) must negative pregnancy serum test screen medication dispense Absence Hp infection , establish negative 13Curea breath test ( 13CUBT ) Body mass index ( BMI ) 1833 kg/m2 , weight 50 135kg . BMI calculation : BMI = weight ( kg ) / height ( ) 2 Documentation significant past history gastrointestinal disease require therapy Patients baseline pH record indicative abnormal acid secretory pattern Significant concurrent disease clinical illness within 14 day initial screen visit Use prescription medication within 14 day initial screening visit , exception oral contraceptive medication , nonsystemic medication topical medication skin condition , nasal spray allergy relief Use either overthecounter ( OTC ) prescription histamine2 receptor antagonist ( H2RAs ) , and/or proton pump inhibitor ( PPIs ) prokinetics , antibiotic bismuth compound within 28 day screen 13CUBT Use OTC medication within 7 day initial screening visit , exception acetaminophen ( daily maximum 2g ) , OTC eye drop , nasal drop spray allergy relief.10 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Acid Reflux</keyword>
	<keyword>Proton Pump Inhibitor</keyword>
	<keyword>GERD</keyword>
</DOC>